Cargando…

TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer

(1) Background: Bevacizumab-based regimens are a standard treatment for metastatic colorectal cancer (mCRC) patients, however meaningful clinical biomarkers for treatment benefit remain scarce. (2) Methods: Tumor samples from 36 mCRC patients treated with bevacizumab-based chemotherapy underwent com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Hung-Chih, You, Jeng-Fu, Chen, Shu-Jen, Chen, Hua-Chien, Yeh, Chien-Yuh, Tsai, Wen-Sy, Hung, Hsin-Yuan, Yang, Tsai-Sheng, Lapke, Nina, Tan, Kien Thiam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721375/ https://www.ncbi.nlm.nih.gov/pubmed/31366114 http://dx.doi.org/10.3390/cancers11081079

Ejemplares similares

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
por: Hsu, Hung-Chih, et al.
Publicado: (2018)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma
por: Lapke, Nina, et al.
Publicado: (2016)

Genetic alterations and their therapeutic implications in epithelial ovarian cancer
por: Lapke, Nina, et al.
Publicado: (2021)

TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study
por: Kamiza, Abram Bunya, et al.
Publicado: (2016)

Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients
por: Tsai, Wen-Sy, et al.
Publicado: (2016)

Association of Preoperative Physical Activity with Short- and Long-Term Outcomes in Patients Undergoing Palliative Resection for Metastatic Colorectal Cancer: An Inverse Probability of Treatment Weighting Analysis
por: Cheng, Ching-Chung, et al.
Publicado: (2022)

Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab
por: Tao, Chi-Wei, et al.
Publicado: (2020)

Short- and medium-term outcomes of intracorporeal versus extracorporeal anastomosis in laparoscopic right colectomy: a propensity score-matched study
por: Liao, Chun-Kai, et al.
Publicado: (2021)

Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study
por: Cheng, Wen-Chien, et al.
Publicado: (2023)

TP53 alterations in relapsed childhood acute lymphoblastic leukemia
por: Yu, Chih‐Hsiang, et al.
Publicado: (2019)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
por: Hsu, Hung‐Chih, et al.
Publicado: (2019)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
por: Chen, Tom Wei-Wu, et al.
Publicado: (2023)

A Prediction Model for Metachronous Peritoneal Carcinomatosis in Patients with Stage T4 Colon Cancer after Curative Resection
por: Tsai, Tzong-Yun, et al.
Publicado: (2021)

Usefulness of close surveillance for rectal cancer patients after neoadjuvant chemoradiotherapy
por: Hsu, Yu-Jen, et al.
Publicado: (2022)

Survival analysis of local excision vs total mesorectal excision for middle and low rectal cancer in pT1/pT2 stage and intermediate pathological risk
por: Lai, I-Li, et al.
Publicado: (2019)

TP53 structural variants in metastatic prostatic carcinoma
por: Sirohi, Deepika, et al.
Publicado: (2019)

Prognostic value of regional lymph node involvement in patients with metastatic colorectal cancer: palliative versus curative resection
por: Kuo, Ya-Ting, et al.
Publicado: (2021)

Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer
por: Cheng, Fiona Tsui-Fen, et al.
Publicado: (2019)

Pharmacological Activation Of Aldehyde Dehydrogenase 2 Protects Against Heatstroke-Induced Acute Lung Injury by Modulating Oxidative Stress and Endothelial Dysfunction
por: Tsai, Hsiao-Ya, et al.
Publicado: (2021)

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
por: Chiang, Ting-Yu, et al.
Publicado: (2023)

Decreasing Postoperative Pulmonary Complication Following Laparoscopic Surgery in Elderly Individuals with Colorectal Cancer: A Competing Risk Analysis in a Propensity Score–Weighted Cohort Study
por: Chern, Yih-Jong, et al.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()
por: Lu, Chien-Yu, et al.
Publicado: (2015)

A case report of the sustained and rapid response of bevacizumab in a TP53-positive breast cancer and liver metastatic patient through personalized medicine
por: Eskandarion, Mohammad Reza, et al.
Publicado: (2022)

Gender Differences and the Trend in the Acute Myocardial Infarction: A 10-Year Nationwide Population-Based Analysis
por: Yang, Hung-Yu, et al.
Publicado: (2012)

Increased risk of aortic aneurysm and dissection in patients with Sjögren’s syndrome: a nationwide population-based cohort study in Taiwan
por: Tsai, Yi-Da, et al.
Publicado: (2018)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

In vitro activities of antimicrobial combinations against planktonic and biofilm forms of Stenotrophomonas maltophilia
por: Su, Bo-An, et al.
Publicado: (2023)

Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
por: Zhou, Jie, et al.
Publicado: (2022)

Effects of a Floor Hockey Intervention on Motor Proficiency, Physical Fitness, and Adaptive Development in Youths with Mild Intellectual Disabilities
por: Hsu, Po-Jen, et al.
Publicado: (2021)

Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports
por: Li, Ching-Chun, et al.
Publicado: (2018)

Perianal Basal Cell Carcinoma—A Systematic Review and Meta-Analysis of Real-World Data
por: Tsai, Tzong-Yun, et al.
Publicado: (2023)

Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer
por: Zhang, Wensheng, et al.
Publicado: (2022)

Accessing a New Dimension in TP53 Biology: Multiplex Long Amplicon Digital PCR to Specifically Detect and Quantitate Individual TP53 Transcripts
por: Lasham, Annette, et al.
Publicado: (2020)

Efficient and Safe Method for Splenic Flexure Mobilization in Laparoscopic Left Hemicolectomy: A Propensity Score–weighted Cohort Study
por: Hsu, Yu-Jen, et al.
Publicado: (2020)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread
por: Hsu, Hung-Chih, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ei8uftm34d59a63emlfthf5i4b